Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02523469 · ClinicalTrials.gov registry record · Phase 1
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT02523469 is a Phase 1 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 67 participants.
The verdict
NCT02523469, a Phase 1 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of the study is to define the safety and tolerability of this drug combination. The study will also define the response rate of patients with advanced and unresectable NSCLC.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL ALT-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2016-01-08 |
| Est. Completion | 2023-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02523469
The ClinicalTrials.gov registry entry for NCT02523469 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02523469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02523469 about?
NCT02523469 is a clinical study titled "ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer". The purpose of the study is to define the safety and tolerability of this drug combination. The study will also define the response rate of patients with advanced and unresectable NSCLC.
What is the current status of trial NCT02523469?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2016-01-08. Estimated completion is 2023-02-24.
What interventions are being tested in trial NCT02523469?
The interventions under investigation include: Nivolumab (BIOLOGICAL), ALT-803 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02523469?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.